Pillai et al found a slight increase in pneumonitis risk with PD‐1 inhibitors.25 It should be noted that no RCT to date has directly compared the risk of immune‐related pneumonitis between PD‐1 and PD‐L1 inhibitors. This evidence concerns the gene CD274 and pneumonitis.